BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock suffered a major decline of -10.4% on 9/30/20. The shares closed at $3.43. Moreover, this decline was accompanied by exceptionally high trading volume at 205% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -8.9% during the last week.
Current PriceTarget Research Rating
BCRX is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BCRX has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. BCRX has a very low Appreciation Score of 2 but a good Power Rating of 79, and the Low Neutral Value Trend Rating results.
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.